NO308772B1 - Sublingual eller buckal farmasoytisk blanding inneholdende trans-5-klor-2-metyl-2,3,3a,12b-tetrahydro-1H-dibenz[2,3:6,7]oksepino[4,5-c]pyrrol, samt anvendelse av forbindelsen for fremstilling av farmasoytisk blanding - Google Patents

Sublingual eller buckal farmasoytisk blanding inneholdende trans-5-klor-2-metyl-2,3,3a,12b-tetrahydro-1H-dibenz[2,3:6,7]oksepino[4,5-c]pyrrol, samt anvendelse av forbindelsen for fremstilling av farmasoytisk blanding

Info

Publication number
NO308772B1
NO308772B1 NO19963639A NO963639A NO308772B1 NO 308772 B1 NO308772 B1 NO 308772B1 NO 19963639 A NO19963639 A NO 19963639A NO 963639 A NO963639 A NO 963639A NO 308772 B1 NO308772 B1 NO 308772B1
Authority
NO
Norway
Prior art keywords
pharmaceutical composition
sublingual
buccal
oxepino
dibenz
Prior art date
Application number
NO19963639A
Other languages
English (en)
Norwegian (no)
Other versions
NO963639D0 (no
NO963639L (no
Inventor
Leonardus Petrus Carla Delbressine
Johannes Hubertus Wieringa
Original Assignee
Akzo Nobel Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=8216678&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO308772(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Akzo Nobel Nv filed Critical Akzo Nobel Nv
Publication of NO963639D0 publication Critical patent/NO963639D0/no
Publication of NO963639L publication Critical patent/NO963639L/no
Publication of NO308772B1 publication Critical patent/NO308772B1/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/006—Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
NO19963639A 1994-03-02 1996-08-30 Sublingual eller buckal farmasoytisk blanding inneholdende trans-5-klor-2-metyl-2,3,3a,12b-tetrahydro-1H-dibenz[2,3:6,7]oksepino[4,5-c]pyrrol, samt anvendelse av forbindelsen for fremstilling av farmasoytisk blanding NO308772B1 (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP94200521 1994-03-02
PCT/EP1995/000765 WO1995023600A1 (en) 1994-03-02 1995-03-01 Sublingual or buccal pharmaceutical composition

Publications (3)

Publication Number Publication Date
NO963639D0 NO963639D0 (no) 1996-08-30
NO963639L NO963639L (no) 1996-10-30
NO308772B1 true NO308772B1 (no) 2000-10-30

Family

ID=8216678

Family Applications (2)

Application Number Title Priority Date Filing Date
NO19963639A NO308772B1 (no) 1994-03-02 1996-08-30 Sublingual eller buckal farmasoytisk blanding inneholdende trans-5-klor-2-metyl-2,3,3a,12b-tetrahydro-1H-dibenz[2,3:6,7]oksepino[4,5-c]pyrrol, samt anvendelse av forbindelsen for fremstilling av farmasoytisk blanding
NO2010024C NO2010024I2 (no) 1994-03-02 2010-12-13 Trans-5-klor-2-metyl-2,3,3a,12b-tetrahydro-1H-dibenz[2,3:6,7]oksepino[4,5-c]pyrrol eller et salt derav

Family Applications After (1)

Application Number Title Priority Date Filing Date
NO2010024C NO2010024I2 (no) 1994-03-02 2010-12-13 Trans-5-klor-2-metyl-2,3,3a,12b-tetrahydro-1H-dibenz[2,3:6,7]oksepino[4,5-c]pyrrol eller et salt derav

Country Status (23)

Country Link
US (1) US5763476A (OSRAM)
EP (1) EP0746317B1 (OSRAM)
JP (2) JP4099224B2 (OSRAM)
KR (1) KR100330942B1 (OSRAM)
CN (1) CN1079670C (OSRAM)
AT (1) ATE167057T1 (OSRAM)
AU (1) AU692530B2 (OSRAM)
BR (2) BR9506924A (OSRAM)
CA (1) CA2182981C (OSRAM)
CZ (1) CZ284633B6 (OSRAM)
DE (2) DE69502939T2 (OSRAM)
DK (1) DK0746317T3 (OSRAM)
ES (1) ES2118584T3 (OSRAM)
FI (1) FI117923B (OSRAM)
FR (1) FR10C0056I2 (OSRAM)
HK (1) HK1008417A1 (OSRAM)
HU (1) HU225051B1 (OSRAM)
LU (1) LU91751I2 (OSRAM)
NO (2) NO308772B1 (OSRAM)
NZ (1) NZ282394A (OSRAM)
PL (1) PL180465B1 (OSRAM)
RU (1) RU2139051C1 (OSRAM)
WO (1) WO1995023600A1 (OSRAM)

Families Citing this family (71)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2418499A (en) * 1997-12-19 1999-07-12 Akzo Nobel N.V. Org-5222 in the treatment of depression
EP1485296B1 (en) * 2002-02-13 2011-07-20 Michael K. Weibel Drug dose - form and method of manufacture
US7306812B2 (en) 2003-05-09 2007-12-11 Cephalon, Inc. Dissolvable backing layer for use with a transmucosal delivery device
US7276246B2 (en) * 2003-05-09 2007-10-02 Cephalon, Inc. Dissolvable backing layer for use with a transmucosal delivery device
KR20060011873A (ko) * 2003-05-16 2006-02-03 화이자 프로덕츠 인코포레이티드 비정형 항정신약과 ｇａｂａ 조절제, 항경련성 약물 또는 벤조다이아제핀의 치료 혼합물
TWI327915B (en) * 2003-06-12 2010-08-01 Organon Nv Pharmaceutical composition comprising antipsychotic agent and use of the antipsychotic agent for treating patients with overweight
MXPA06002766A (es) * 2003-09-22 2006-12-14 Baxter Int Esterilizacion a alta presion para esterilizar terminalmente preparaciones farmaceuticas y productos medicos.
MXPA06013163A (es) * 2004-05-11 2007-02-13 Pfizer Prod Inc Combinacion de antipsicoticos atipicos y antagonistas del receptor 5-ht1b.
GB0416861D0 (en) * 2004-07-29 2004-09-01 Quadrant Drug Delivery Ltd Composition
RU2403039C2 (ru) * 2004-10-15 2010-11-10 H.B.Opганон Лечение биполярных расстройств и сопутствующих симптомов
ES2293626T3 (es) * 2005-04-07 2008-03-16 N.V. Organon Forma cristalina del maleato de asenapina.
US7872147B2 (en) 2005-04-07 2011-01-18 N. V. Organon Intermediate compounds for the preparation of trans-5-chloro-2-methyl-2,3,3a,12b-tetrahydro-1H-dibenz[2,3:6,7]oxepino[4,5-c]pyrrole
AR063188A1 (es) 2005-04-07 2009-01-14 Organon Nv Compuestos intermediarios para la preparacion de trans -5-cloro-2-netil-2,3,3a,12b- tetrahidro-1h-dibenz (2,3:6,7)- oxepina (4,5c) pirrol
US7741358B2 (en) * 2005-04-14 2010-06-22 N.V. Organon Crystal form of asenapine maleate
US7750167B2 (en) 2006-07-05 2010-07-06 N.V. Organon Process for the preparation of asenapine and intermediate products used in said process
US7875729B2 (en) 2007-01-05 2011-01-25 Synthon Bv Process for making asenapine
UY31531A1 (es) * 2007-12-17 2009-08-03 Sales derivadas de 8-oxoadenina composiciones farmacéuticas que las contienen y su uso en terapia como moduladores de receptor tipo toll (tlr)
EP2321011A1 (en) * 2008-06-25 2011-05-18 Pfizer Inc. Diaryl compounds and uses thereof
WO2010127674A1 (en) * 2009-05-06 2010-11-11 Sunin K/S Transdermal compositions of asenapine for the treatment of psychiatric disorders
CA2766291C (en) 2009-06-24 2016-06-21 Msd Oss B.V. Injectable formulations containing asenapine and method of treatment using same
TW201118102A (en) 2009-07-29 2011-06-01 Organon Nv Hydroxyasenapine compounds, derivatives thereof and pharmaceutical compositions comprising same
AU2011268335A1 (en) 2010-06-18 2013-01-10 Dr. Reddy's Laboratories Ltd. Asenapine maleate
KR101810717B1 (ko) 2010-07-29 2017-12-19 라보라토리오스 레스비, 에스.엘. 아세나핀을 제조하는 신규한 방법
WO2012038975A2 (en) * 2010-09-22 2012-03-29 Msn Laboratories Limited Process for the preparation of (3ars,12brs)-5-chloro-2-methyl-2,3,3a12b-tetrahydro-1hdibenzo[2,3:6,7] oxepino [4,5-c]pyrrole maleate and it's pharmaceutical composition thereof
DK2640391T3 (da) 2010-11-15 2016-02-15 Agenebio Inc Pyridazinderivater, sammensætninger og fremgangsmåder til behandling af kognitiv svækkelse
WO2012066565A2 (en) 2010-11-16 2012-05-24 Cadila Healthcare Limited Asenapine maleate amorphous and crystalline form and process for preparation thereof
EP2468750A1 (en) 2010-12-13 2012-06-27 Chemo Ibérica, S.A. Polymorphic forms of asenapine maleate and processes for their preparation
WO2012123325A1 (en) 2011-03-11 2012-09-20 Medichem S.A. NEW CRYSTAL FORMS OF THE SALT OF TRANS-5-CHLORO-2-METHYL-2,3,3A,12b-TETRAHYDRO-1H-DIBENZO[2,3:6,7]OXEPINO[4,5-c]PYRROLE WITH MALEIC ACID
EP2524919A1 (en) 2011-05-17 2012-11-21 Sandoz AG Novel crystalline salts of Asenapine with organic Di-acids and Tri-acids
US9533994B2 (en) 2011-05-18 2017-01-03 Laboratorios Lesvi S.L. Monoclinic crystalline form of asenapine maleate with a specific particle size distribution
EP2709616B1 (en) * 2011-05-18 2018-01-24 Laboratorios Lesvi, S.L. Synthesis of a stable micronised monoclinic form of asenapine maleate
EP2572703A1 (en) 2011-09-21 2013-03-27 Hexal AG Compressed oral dosage form for asenapine maleate
WO2013041604A1 (en) 2011-09-21 2013-03-28 Sandoz Ag Crystal form of asenapine maleate
CN102657635B (zh) * 2012-05-04 2013-08-07 上海现代药物制剂工程研究中心有限公司 具有微孔的海绵状的阿塞那平舌下膜剂及其制备方法
ITMI20121810A1 (it) 2012-10-24 2014-04-25 Chemo Iberica Sa Poliformi di maleato di asenapina e processo per la loro preparazione
JP6440625B2 (ja) 2012-11-14 2018-12-19 ザ・ジョンズ・ホプキンス・ユニバーシティー 精神分裂病を処置するための方法および組成物
WO2014090386A1 (en) 2012-12-11 2014-06-19 Alfred E. Tiefenbacher (Gmbh & Co. Kg) Orally disintegrating tablet containing asenapine
RU2015128794A (ru) 2012-12-20 2017-01-25 КАШИВ ФАРМА, ЭлЭлСи Композиция перорально распадающейся таблетки, обеспечивающая повышенную биодоступность
CN103893139B (zh) * 2012-12-28 2018-06-08 石药集团中奇制药技术（石家庄）有限公司 一种阿塞那平组合物及其制备方法
CN103120688A (zh) * 2013-01-11 2013-05-29 盛世泰科生物医药技术(苏州)有限公司 一种闪释制剂的药物组合
WO2014116770A1 (en) 2013-01-23 2014-07-31 Arx, Llc Production of unit dose constructs
WO2014127786A1 (en) 2013-02-22 2014-08-28 Zentiva, K.S. Orally disintegrating pharmaceutical composition comprising asenapine
IN2013MU02206A (OSRAM) * 2013-06-28 2015-06-12 Alembic Pharmaceuticals Ltd
EP4032889A1 (en) 2013-12-20 2022-07-27 Agenebio, Inc. Benzodiazepine derivatives, compositions, and methods for treating cognitive impairment
WO2015125152A2 (en) * 2014-02-18 2015-08-27 Hetero Research Foundation Pharmaceutical compositions of asenapine
MX388258B (es) 2014-04-04 2025-03-19 Intra Cellular Therapies Inc Gamma-carbolinas fusionadas con heterociclos sustituidas con deuterio.
TR201509009A1 (en) * 2014-12-11 2017-02-21 Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi THIN FILM STRIP OF ASENAPINE
US11154510B2 (en) 2015-06-11 2021-10-26 Alrise Biosystems Gmbh Process for the preparation of drug loaded microparticles
MA42624A (fr) 2015-06-19 2021-04-28 Agenebio Inc Dérivés de benzodiazépine, compositions et méthodes de traitement de la déficience cognitive
PT3407888T (pt) 2016-01-26 2021-03-19 Intra Cellular Therapies Inc Compostos de piridopirroloquinoxalina, suas composições e utilizações
JP6686168B2 (ja) 2016-03-25 2020-04-22 イントラ−セルラー・セラピーズ・インコーポレイテッドＩｎｔｒａ−Ｃｅｌｌｕｌａｒ Ｔｈｅｒａｐｉｅｓ， Ｉｎｃ． 有機化合物
US10085971B2 (en) 2016-08-22 2018-10-02 Navinta Iii Inc Pharmaceutical solution of asenapine for sublingual or buccal use
US20180170941A1 (en) 2016-12-19 2018-06-21 Agenebio, Inc. Benzodiazepine derivatives, compositions, and methods for treating cognitive impairment
US11505555B2 (en) 2016-12-19 2022-11-22 Agenebio, Inc. Benzodiazepine derivatives, compositions, and methods for treating cognitive impairment
KR102614709B1 (ko) 2016-12-20 2023-12-18 에르테에스 로만 테라피-시스테메 아게 아세나핀 및 폴리실록산 또는 폴리이소부틸렌을 함유하는 경피흡수 치료 시스템
EP3338768B1 (en) 2016-12-20 2019-10-30 LTS Lohmann Therapie-Systeme AG Transdermal therapeutic system containing asenapine
WO2018126140A1 (en) 2016-12-29 2018-07-05 Intra-Cellular Therapies, Inc. Organic compounds
US10906906B2 (en) 2016-12-29 2021-02-02 Intra-Cellular Therapies, Inc. Organic compounds
CN116327770B (zh) 2017-03-24 2025-10-31 细胞内治疗公司 新组合物和方法
US11033512B2 (en) 2017-06-26 2021-06-15 Lts Lohmann Therapie-Systeme Ag Transdermal therapeutic system containing asenapine and silicone acrylic hybrid polymer
CA3094204A1 (en) 2018-03-16 2019-09-19 Intra-Cellular Therapies, Inc. Novel methods
MX2020009928A (es) 2018-03-23 2021-01-08 Intra Cellular Therapies Inc Compuestos organicos.
CN112601749B (zh) 2018-06-19 2024-03-26 艾吉因生物股份有限公司 用于治疗认知损害的苯并二氮杂环庚三烯衍生物，组合物和方法
AU2019291060B2 (en) 2018-06-20 2024-09-05 Lts Lohmann Therapie-Systeme Ag Transdermal therapeutic system containing asenapine
US12329862B2 (en) 2018-06-20 2025-06-17 Lts Lohmann Therapie-Systeme Ag Transdermal therapeutic system containing asenapine
EP3843729A4 (en) 2018-08-29 2022-06-01 Intra-Cellular Therapies, Inc. NEW COMPOSITIONS AND METHODS
EP3843738A4 (en) 2018-08-31 2022-06-01 Intra-Cellular Therapies, Inc. NEW METHODS
US10695345B2 (en) 2018-08-31 2020-06-30 Intra-Cellular Therapies, Inc. Pharmaceutical capsule compositions comprising lumateperone mono-tosylate
JP7673040B2 (ja) 2019-07-07 2025-05-08 イントラ－セルラー・セラピーズ・インコーポレイテッド 新規方法
US12414948B2 (en) 2022-05-18 2025-09-16 Intra-Cellular Therapies, Inc. Methods
WO2024039886A1 (en) 2022-08-19 2024-02-22 Agenebio, Inc. Benzazepine derivatives, compositions, and methods for treating cognitive impairment

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL7605526A (nl) * 1976-05-24 1977-11-28 Akzo Nv Nieuwe tetracyclische derivaten.
GB1548022A (en) * 1976-10-06 1979-07-04 Wyeth John & Brother Ltd Pharmaceutial dosage forms
IE45770B1 (en) * 1976-10-06 1982-11-17 Wyeth John & Brother Ltd Pharmaceutical dosage forms
FR2480283A1 (fr) * 1980-04-10 1981-10-16 Science Union & Cie Nouveaux derives tricycliques, leurs procedes de preparation et leur utilisation comme medicament
JPS5967218A (ja) * 1982-10-07 1984-04-16 Grelan Pharmaceut Co Ltd 軟質な口腔製剤
GB8613688D0 (en) * 1986-06-05 1986-07-09 Euro Celtique Sa Pharmaceutical composition
CA2027243A1 (en) * 1989-10-17 1991-04-18 Everett H. Ellinwood, Jr. Intraoral formulated trifluorobenzodiazepines and the use thereof
DE69232374T2 (de) * 1991-04-08 2002-08-29 Koken Co. Ltd., Tokyo Poröse feste zubereitung, die eine physiologische aktive proteinverbindung enthält
EP0569096A1 (en) * 1992-05-08 1993-11-10 Akzo Nobel N.V. Depot preparation
ZA933134B (en) * 1992-05-08 1993-11-30 Akzo Nv Depot preparation

Also Published As

Publication number Publication date
CA2182981C (en) 2006-10-17
EP0746317A1 (en) 1996-12-11
CZ254196A3 (en) 1997-10-15
WO1995023600A1 (en) 1995-09-08
NO963639D0 (no) 1996-08-30
FR10C0056I2 (OSRAM) 2011-11-25
DK0746317T3 (da) 1999-03-22
DE122010000050I2 (de) 2011-07-21
RU2139051C1 (ru) 1999-10-10
CA2182981A1 (en) 1995-09-08
NO963639L (no) 1996-10-30
CZ284633B6 (cs) 1999-01-13
JP4099224B2 (ja) 2008-06-11
FI963398L (fi) 1996-08-30
FR10C0056I1 (OSRAM) 2011-01-28
KR100330942B1 (ko) 2002-11-16
ES2118584T3 (es) 1998-09-16
AU1947895A (en) 1995-09-18
MX9603713A (es) 1997-12-31
NO2010024I2 (no) 2012-04-10
EP0746317B1 (en) 1998-06-10
FI963398A0 (fi) 1996-08-30
CN1079670C (zh) 2002-02-27
HU225051B1 (en) 2006-05-29
PL316080A1 (en) 1996-12-23
NZ282394A (en) 1997-12-19
CN1143320A (zh) 1997-02-19
BR1100625A (pt) 1999-12-28
ATE167057T1 (de) 1998-06-15
AU692530B2 (en) 1998-06-11
JP4616810B2 (ja) 2011-01-19
LU91751I2 (fr) 2011-01-04
DE69502939D1 (de) 1998-07-16
DE69502939T2 (de) 1998-10-22
NO2010024I1 (no) 2011-01-03
HK1008417A1 (en) 1999-05-07
PL180465B1 (pl) 2001-02-28
JPH09509674A (ja) 1997-09-30
HU9602383D0 (en) 1996-10-28
HUT76319A (en) 1997-08-28
JP2006342178A (ja) 2006-12-21
BR9506924A (pt) 1997-09-30
US5763476A (en) 1998-06-09
DE122010000050I1 (de) 2011-05-05
FI117923B (fi) 2007-04-30

Similar Documents

Publication Publication Date Title
NO308772B1 (no) Sublingual eller buckal farmasoytisk blanding inneholdende trans-5-klor-2-metyl-2,3,3a,12b-tetrahydro-1H-dibenz[2,3:6,7]oksepino[4,5-c]pyrrol, samt anvendelse av forbindelsen for fremstilling av farmasoytisk blanding
CA2293823A1 (en) 4"-substituted-9-deoxo-9a-aza-9a-homoerythromycin a derivatives
CA2258548A1 (en) Phenylamino-substituted tricyclic derivatives for treatment of hyperproliferative diseases
CA2272705A1 (en) Fused bicyclic pyrimidine derivatives
CA2293397A1 (en) C-4''-substituted macrolide derivatives
CA2316921A1 (en) Aryl fused azapolycyclic compounds
RU96120090A (ru) Сублингвальная или трансбуккальная фармацевтическая композиция
AU2002359164A1 (en) Use of oxindole derivatives in the treatment of dementia related diseases, alzheimer's disease and conditions associated with glycogen synthase kinase-3
CA2129995A1 (en) Piperidinyl thiacyclic derivatives
AU3563695A (en) Novel piperidine derivatives with paf antagonist activity
CA2314154A1 (en) Azepine or larger medium ring derivatives and their use as pharmaceuticals
AU1579688A (en) Bisphenylalkylpiperazine derivatives, a method of their preparation and a pharmaceutical preparation
TW252979B (OSRAM)
AU1998995A (en) Substituted fused and bridged bicyclic compounds as therapeutic agents
NO308852B1 (no) Indol-2,3-dion-3-oksim-derivater, farmasøytisk blanding og anvendelse av forbindelsen
AU6519596A (en) Use of allylamine derivatives such as terbinafine, in the manufacture of a medicament for the treatment of helicobacter pylori infection of associated diseases
AU5608790A (en) New pyrrolidone derivatives, the process for their preparation and the pharmaceutical compositions containing them
IL115004A0 (en) Use of substituted 6-amino-4h-pyrans as medicaments, certain novel such compounds and their preparation
EP0276805A3 (en) Substituted 3-phenyl-7h-thiazoloû3,2-b¨û1,2,4¨triazin-7-ones, processes for their preparation, medicaments containing them and their use as well as some of the intermediates obtained during the preparation of said compounds
WO2000037465A3 (en) Novel derivatives of swainsonine, processes for their preparation, and their use as therapeutic agents
MXPA99003849A (es) Derivados 9a, 11b-deshidro de 9-oxima-3-ceto-6-0-metileritromicina.

Legal Events

Date Code Title Description
SPCF Filing of supplementary protection certificate

Free format text: PRODUCT NAME: SYCREST-ASENAPIN; NAT. REG. NO/DATE: EU/1/10/640/001/NO- 20101115; FIRST REG. NO/DATE: EU/1/10/640/001-006 20100901

Spc suppl protection certif: 2010024

Filing date: 20101213

SPCG Granted supplementary protection certificate

Free format text: PRODUCT NAME: SYCREST-ASENAPIN; NAT. REG. NO/DATE: EU/1/10/640/001/NO- 20101115; FIRST REG. NO/DATE: EU/1/10/640/001-006 20100901

Spc suppl protection certif: 2010024

Filing date: 20101213

Extension date: 20200301

CHAD Change of the owner's name or address (par. 44 patent law, par. patentforskriften)

Owner name: MERCK SHARP & DOHME BV, NL

MK1K Patent expired
SPCX Expiry of an spc

Spc suppl protection certif: 2010024

Effective date: 20200302